Drug intelligence / Profile preview

Amivita

Development stage: Unknown
Lead developer: Mallinckrodt
Modality: Small Molecules
Administration: Subcutaneous

Overview

Amivita is a compound composed of amino acids and vitamins. It is being investigated for its safety and efficacy in patients with Amyotrophic lateral sclerosis (ALS). Previous studies have indicated that Amivita is effective for neuronal injury and retrospective analysis suggests it can slow down the progression of ALS. It is currently undergoing a self-controlled clinical trial in ALS patients who are already receiving standard treatments like Riluzole but whose condition is worsening.

Brand names: Amivita

Beyond the preview

Go deeper on Amivita.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amivita.

Explore the full profile